UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Blood, 2000-03, Vol.95 (6), p.1925-1930

2000

Link zum Volltext

Verfügbarkeit prüfen

Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Clinical cancer research, 2005-10, Vol.11 (19), p.6787-6792

2005

Link zum Volltext

Verfügbarkeit prüfen

Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma

Journal of clinical oncology, 2000-02, Vol.18 (4), p.804-812

2000

Link zum Volltext

Verfügbarkeit prüfen

Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis

Digestive diseases and sciences, 2002-09, Vol.47 (9), p.1909-1914

2002

Link zum Volltext

Verfügbarkeit prüfen

Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma

Clinical cancer research, 1999-09, Vol.5 (9), p.2426-2430

1999

Link zum Volltext

Verfügbarkeit prüfen

Detection of Chromosomal Aneuploidy by Interphase Fluorescence In Situ Hybridization in Bronchoscopically Gained Cells From Lung Cancer Patients

Chest, 1997-06, Vol.111 (6), p.1691-1696

1997

Link zum Volltext

Verfügbarkeit prüfen

Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma

Clinical cancer research, 2003-02, Vol.9 (2), p.820-826

2003

Link zum Volltext

Verfügbarkeit prüfen

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

Blood, 2011-11, Vol.118 (21), p.4494-4494

2011

Link zum Volltext

Verfügbarkeit prüfen

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Blood, 2010-11, Vol.116 (21), p.2955-2955

2010

Link zum Volltext

Verfügbarkeit prüfen

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy

Blood, 1998-08, Vol.92 (3), p.802-809

1998

Link zum Volltext

Verfügbarkeit prüfen

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy

Blood, 1998-08, Vol.92 (3), p.802-809

1998

Link zum Volltext

Verfügbarkeit prüfen

DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies

Cancer, 2004-06, Vol.100 (12), p.2598-2606

2004

Link zum Volltext

Verfügbarkeit prüfen

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis

Blood, 2007-11, Vol.110 (11), p.4845-4845

2007

Link zum Volltext

Verfügbarkeit prüfen

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion

Blood, 2005-11, Vol.106 (11), p.509-509

2005

Link zum Volltext

Verfügbarkeit prüfen

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma

European journal of haematology, 2003-09, Vol.71 (3), p.179-183

2003

Link zum Volltext

Verfügbarkeit prüfen

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

Blood, 2006-11, Vol.108 (11), p.3398-3398

2006

Link zum Volltext

Verfügbarkeit prüfen

Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance

British journal of haematology, 2002-06, Vol.117 (4), p.852-859

2002

Link zum Volltext

Verfügbarkeit prüfen

The biology of multiple myeloma

Journal of cancer research and clinical oncology, 2000-08, Vol.126 (8), p.441-447

2000

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization

British journal of haematology, 2000-09, Vol.110 (3), p.605-609

2000

Link zum Volltext

Verfügbarkeit prüfen

Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication byallogeneic stem cell transplantation

Clinical cancer research, 2005, Vol.11 (19), p.6787-6792

2005

Link zum Volltext

Verfügbarkeit prüfen

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q

Blood, 2004-11, Vol.104 (11), p.3459-3459

2004

Link zum Volltext

Verfügbarkeit prüfen

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance

Blood, 2004-11, Vol.104 (11), p.4873-4873

2004

Link zum Volltext

Verfügbarkeit prüfen

Aneuploidy of chromosome 7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridisation

Lung cancer (Amsterdam, Netherlands), 2000-06, Vol.28 (3), p.225-235

2000

Link zum Volltext

Verfügbarkeit prüfen

Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undedetermined significance

British journal of haematology, 1998-12, Vol.103 (4), p.1161-1163

1998

Link zum Volltext

Verfügbarkeit prüfen

The nature of the cell in multiple myeloma / Aughors' reply

The American journal of pathology, 1999-09, Vol.155 (3), p.1005

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(43)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(23)
Humans
(22)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Female
(14)
Male
(13)
Hematology
(12)
Middle Aged
(12)
In Situ Hybridization, Fluorescence
(11)
Adult
(9)
Aged
(9)
Multiple Myeloma - Genetics
(9)
Oncology
(9)
Hematologic And Hematopoietic Diseases
(8)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)
Prognosis
(8)
Chromosomes, Human, Pair 13
(6)
Multiple Myeloma - Pathology
(6)
Aged, 80 And Over
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma

Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis

Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma

Detection of Chromosomal Aneuploidy by Interphase Fluorescence In Situ Hybridization in Bronchoscopically Gained Cells From Lung Cancer Patients

Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy

DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance

The biology of multiple myeloma

Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization

Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication byallogeneic stem cell transplantation

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance

Aneuploidy of chromosome 7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridisation

Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undedetermined significance

The nature of the cell in multiple myeloma / Aughors' reply

Suchergebnisse filtern